Stockreport

Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset [Yahoo! Finance]

OmniAb, Inc.  (OABI) 
PDF investigational novel compound with broad potential to treat brain health diseases, excluding the Republic of Korea, China, Hong Kong, Macau and Taiwan Sovargen receiv [Read more]